Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 148 No. 0708 (2018)

First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial – preliminary results

  • Christian Murer
  • Lars C. Huber
  • Thomas Kurowski
  • Astrid Hirt
  • Cécile Robinson
  • Urs Bürgi
  • Christian Benden
DOI
https://doi.org/10.4414/smw.2018.14593
Cite this as:
Swiss Med Wkly. 2018;148:w14593
Published
16.02.2018

Summary

AIMS OF THE STUDY

Cystic fibrosis is the most common genetic disorder in Caucasians. The combination of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector lumacaftor / potentiator ivacaftor (LUM/IVA) has been shown to increase forced expiratory volume in 1 second (FEV1) moderately, but predominantly reduce acute exacerbation rate (AER) in Phe508del homozygous cystic fibrosis patients; however, patients with FEV1 <40% predicted were excluded from studies. We used LUM/IVA on a “compassionate use” basis in cystic fibrosis patients with end-stage pulmonary disease. Our aim was to evaluate if this patient cohort tolerates LUM/IVA treatment and if there is clinical stabilisation. Lung transplantation (LTX) is the ultimate treatment option for these patients despite maximal therapy. If LTX candidates stabilise clinically, conditions for LTX, when it is indicated, improve. This is particularly important in countries such as Switzerland with a low organ donation rate and long waiting times for suitable donor organs.

METHODS

We included all patients from the Adult Cystic Fibrosis Centre at the University Hospital Zurich with Phe508del homozygous genotype and a predicted FEV1 <40% or being evaluated or already listed for LTX. Clinical outcome data comprised AER, 6-minute walking distance (6-MWD), FEV1, forced vital capacity (FVC), mid-expiratory flow (MEF 25–75%), sweat chloride, body mass index (BMI) and quality of life. Respiratory-related adverse events (RAEs) were recorded. LUM/IVA treatment was initiated at a low dose and the dose increased stepwise.

RESULTS

Twenty patients were on trial with LUM/IVA; at the cut-off date, 6-month follow-up was complete for 10 patients. RAEs were severe and occurred early. The dropout rate due to RAE or lack of clinical success was 20%. Median AER decreased from 2.5 in the 6 months pre-treatment to 1 during the observation period. FEV1 increased from 32 to 34.5% predicted, p = 0.292. The 6-MWD increased by a median 33 m (p = 0.6086). Sweat chloride decreased significantly by a median of 25 mmol/l (p = 0.0003). Median BMI increased from 19 to 19.9 kg/m2 (p = 0.1488). At the cut-off, three previously listed patients were paused on the transplant waiting list.

CONCLUSION

Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease tolerated LUM/IVA, although RAEs occurred early and were severe. This positive finding was probably due to the stepwise dose increases. There was clinical benefit mainly from reduction in AER and stabilisation of lung function. We propose that all suitable Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease should have a trial of LUM/IVA treatment in experienced centres.

References

  1. WHO. Genomic Resource Centre. Genes and human disease. http://www.who.int/genomics/public/geneticdiseases/en/index2.html.
  2. Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68(4):809–18. doi:https://doi.org/10.1016/0092-8674(92)90155-6.https://doi.org/10.1016/0092-8674(92)90155-6
  3. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4(8):662–74. doi:https://doi.org/10.1016/S2213-2600(16)00023-0.https://doi.org/10.1016/S2213-2600(16)00023-0
  4. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72. doi:https://doi.org/10.1056/NEJMoa1105185.https://doi.org/10.1056/NEJMoa1105185
  5. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al.; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–31. doi:https://doi.org/10.1056/NEJMoa1409547.https://doi.org/10.1056/NEJMoa1409547
  6. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15. doi:https://doi.org/10.1016/j.healun.2014.06.014.https://doi.org/10.1016/j.healun.2014.06.014
  7. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10(Suppl 2):S79–81. doi:https://doi.org/10.1016/S1569-1993(11)60012-X.https://doi.org/10.1016/S1569-1993(11)60012-X
  8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38. doi:https://doi.org/10.1183/09031936.05.00034805.https://doi.org/10.1183/09031936.05.00034805
  9. Wenninger K, Aussage P, Wahn U, Staab D ; German Cystic Fibrosis Questionnaire study group. The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Qual Life Res. 2003;12(1):77–85. doi:https://doi.org/10.1023/A:1022011704399.https://doi.org/10.1023/A:1022011704399
  10. Popowicz N, Wood J, Tai A, Morey S, Mulrennan S. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease. J Cyst Fibros. 2017;16(3):392–4. doi:https://doi.org/10.1016/j.jcf.2017.02.009.https://doi.org/10.1016/j.jcf.2017.02.009
  11. Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, et al.; VX-809 TRAFFIC and TRANSPORT study groups. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016;4(8):617–26. doi:https://doi.org/10.1016/S2213-2600(16)30121-7.https://doi.org/10.1016/S2213-2600(16)30121-7
  12. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al.; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527–38. doi:https://doi.org/10.1016/S2213-2600(14)70132-8.https://doi.org/10.1016/S2213-2600(14)70132-8
  13. Fidler MC, Beusmans J, Panorchan P, Van Goor F. Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. J Cyst Fibros. 2017;16(1):41–4. doi:https://doi.org/10.1016/j.jcf.2016.10.002.https://doi.org/10.1016/j.jcf.2016.10.002
  14. Vermeulen F, Lebecque P, De Boeck K, Leal T. Biological variability of the sweat chloride in diagnostic sweat tests: A retrospective analysis. J Cyst Fibros. 2017;16(1):30–5. doi:https://doi.org/10.1016/j.jcf.2016.11.008.https://doi.org/10.1016/j.jcf.2016.11.008
  15. Hubert D, Chiron R, Camara B, Grenet D, Prévotat A, Bassinet L, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16(3):388–91. doi:https://doi.org/10.1016/j.jcf.2017.03.003.https://doi.org/10.1016/j.jcf.2017.03.003
  16. Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, et al.; VX14-809-106 Investigator Group. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2017;S1569-1993(17)30891-3.
  17. Marigowda G, Liu F, Waltz D. Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. J Cyst Fibros. 2017;16(2):246–9. doi:https://doi.org/10.1016/j.jcf.2016.11.001.https://doi.org/10.1016/j.jcf.2016.11.001
  18. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A, et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662–6. doi:https://doi.org/10.1513/AnnalsATS.201701-058OC.https://doi.org/10.1513/AnnalsATS.201701-058OC
  19. Horsley A, Barry P. Orkambi in patients with severe disease - Bumps in the road to CFTR modulation. J Cyst Fibros. 2017;16(3):311–2. doi:https://doi.org/10.1016/j.jcf.2017.04.008.https://doi.org/10.1016/j.jcf.2017.04.008

Most read articles by the same author(s)

<< < 1 2